Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Annovis Bio (NYSE: ANVS) Announces Data From Phase III Study of Buntanetap for Early Parkinson’s

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease and Parkinson’s Disease, has released...

ANVS : 10.75 (-5.12%)
Annovis Bio (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap

Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s...

ANVS : 10.75 (-5.12%)
Annovis Bio (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”),...

ANVS : 10.75 (-5.12%)
Annovis Bio (NYSE: ANVS) Names Four New Members to Executive Team

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

PFE : 29.60 (-1.23%)
ANVS : 10.75 (-5.12%)
Annovis Bio (NYSE: ANVS) Releases Significant Findings from Phase 3 Parkinson’s Study

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 10.75 (-5.12%)
Annovis Bio (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for Alzheimer’s

June is Alzheimer’s & Brain Awareness Month, a time dedicated to raising awareness about Alzheimer’s disease and other forms of dementia, as well as the importance of brain health. Even though the...

ANVS : 10.75 (-5.12%)
Annovis Bio (NYSE: ANVS) Submits Patent Application for New Composition of Buntanetap Matter

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 10.75 (-5.12%)
Annovis Bio (NYSE: ANVS) Announces Upcoming Investor Webcast Focused on PD, Lead Drug Candidate

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), is hosting...

ANVS : 10.75 (-5.12%)
Annovis Bio (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), will be presenting...

ANVS : 10.75 (-5.12%)
Annovis Bio (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug-platform company developing novel therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”),...

ANVS : 10.75 (-5.12%)

Barchart Exclusives

5 'Pick and Shovel' AI Growth Stocks to Scoop Up Now
With AI demand rising and data centers set for explosive growth, these AI infrastructure providers emerge as prime investment opportunities now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar